Literature DB >> 1159316

Mouse model for protoporphyria. I. The liver and hepatic protoporphyrin crystals.

F Gschnait, K Konrad, H Hönigsmann, H Denk, K Wolff.   

Abstract

Outbred albino mice were rendered protoporphyric by a diet containing 2.5% (weight) of griseofulvin. There was a 5-fold increase in liver weight, hepatocellular degeneration and necrosis, cholestasis, ductular proliferation and cirrhosis. Liver protoporphyrin values were elevated and brown pigment granules were present in hepatocytes, Kupffer cells, and bile ducts. The granules showed red fluorescence, birefringence, and, at the ultrastructural level, consisted of aggregates of needle-like crystals. Crystals isolated from such livers showed solubility and absorption characteristics of protoporphyrin; in vitro recrystallization of protoporphyrin, extracted from protoporphyric mouse livers, yielded crystals identical with those observed in vivo, and commercial protoporphyrin exhibited similar morphologic features. The liver pathology and protoporphyrin crystals observed in these animals are identical to the liver pathology and crystals observed in the human disease, erythropoietic protoporphyria. In this mouse model, protoporphyrin crystals are intimately associated with hepatocellular injury and it appears that their accumulation within hepatocytes leads to hepatocellular destruction. A similar pathogenesis is postulated for the hepatic damage that occurs in some cases of erythropoietic protoporphyria.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159316     DOI: 10.1111/1523-1747.ep12598357

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Comparative study of protoporphyrins in erythropoietic protoporphyria and griseofulvin-induced murine protoporphyria. Binding affinities, distribution, and fluorescence spectra in various blood fractions.

Authors:  M B Poh-Fitzpatrick; A A Lamola
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

Review 2.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

3.  Phototoxicity of protoporphyrin as related to its subcellular localization in mice livers after short-term feeding with griseofulvin.

Authors:  S Sandberg; I Romslo
Journal:  Biochem J       Date:  1981-07-15       Impact factor: 3.857

4.  Protoporphyrin hepatopathy. Effects of cholic acid ingestion in murine griseofulvin-induced protoporphyria.

Authors:  M B Poh-Fitzpatrick; J A Sklar; C Goldsman; J H Lefkowitch
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

5.  Protoporphyrin-induced cholestasis in the isolated in situ perfused rat liver.

Authors:  D L Avner; R G Lee; M M Berenson
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

6.  Protoporphyrin overload in unrestrained rats: biochemical and histopathologic characterization of a new model of protoporphyric hepatopathy.

Authors:  M M Berenson; R Kimura; W Samowitz; D Bjorkman
Journal:  Int J Exp Pathol       Date:  1992-10       Impact factor: 1.925

7.  A metabolomic perspective of griseofulvin-induced liver injury in mice.

Authors:  Ke Liu; Jiong Yan; Madhav Sachar; Xinju Zhang; Ming Guan; Wen Xie; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2015-09-05       Impact factor: 5.858

8.  A precursor-inducible zebrafish model of acute protoporphyria with hepatic protein aggregation and multiorganelle stress.

Authors:  Jared S Elenbaas; Dhiman Maitra; Yang Liu; Stephen I Lentz; Bradley Nelson; Mark J Hoenerhoff; Jordan A Shavit; M Bishr Omary
Journal:  FASEB J       Date:  2016-02-02       Impact factor: 5.191

Review 9.  The association between chemical-induced porphyria and hepatic cancer.

Authors:  Andrew G Smith; John R Foster
Journal:  Toxicol Res (Camb)       Date:  2018-06-01       Impact factor: 3.524

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.